Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report

J Diabetes Investig. 2022 Jun;13(6):1105-1108. doi: 10.1111/jdi.13757. Epub 2022 Feb 11.

Abstract

The vaccine for the coronavirus disease 2019 (COVID-19) has been reported to potentially cause or worsen diabetes. A 73-year-old Japanese woman received two doses of Moderna COVID-19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the second vaccination, the patient was diagnosed with new-onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease-susceptible human leukocyte antigen haplotype, DRB1*04:05:01-DQB1*04:01:01. The glucagon stimulation test suggested an insulin-dependent state, and induction of intensive insulin therapy brought about fair glycemic control. The time period from the COVID-19 vaccination to the development of type 1 diabetes was relatively longer than to the onset or exacerbation of type 2 diabetes, as previously reported, suggesting the complicated immunological mechanisms for the destruction of β-cells associated with the vaccination. In recipients with the disease-susceptible haplotypes, one should be cautious about autoimmune responses for several months after the vaccination.

Keywords: COVID-19; Type 1 diabetes; Vaccine.

Publication types

  • Case Reports

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Aged
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Diabetes Mellitus, Type 1*
  • Diabetes Mellitus, Type 2* / etiology
  • Female
  • Genetic Predisposition to Disease
  • Haplotypes
  • Humans
  • Insulin / genetics
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • Insulin
  • 2019-nCoV Vaccine mRNA-1273